Brief: Ryvu Therapeutics Says 'PERO' Project Recommended For Funding By National Centre For Research And Development
22/01/2026 14:55
Jan 22 (Reuters) - Ryvu Therapeutics SA RVU.WA: "PERO" PROJECT RECOMMENDED FOR FUNDING BY NATIONAL CENTRE FOR RESEARCH AND DEVELOPMENT (NCBR) PROJECT AIMS TO CREATE PLATFORM FOR VALIDATION OF THERAPEUTIC TARGETS IN ONCOLOGY TOTAL PROJECT VALUE IS 32.35 MILLION ZLOTYS, RECOMMENDED FUNDING AMOUNT IS 19.96 MILLION ZLOTYS Source text: ID:nEM3DW77Ha Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project